Search for: "Ely Lilly"
Results 381 - 400
of 2,173
Sort by Relevance
|
Sort by Date
Court Of Appeals For Federal Circuit Denies Eli Lilly’s Appeal, Opens Door for Testosterone Generics
5 Dec 2017, 12:29 pm
The Plaintiffs, Eli Lilly and Company, Eli Lilly Export S.A., and Acrux DDS Pty Ltd. had filed a patent infringement lawsuit in the Southern District of Indiana alleging that Defendants, Perrigo Company, Perrigo Israel Pharmaceuticals Ltd., Actavis Laboratories UT, Inc., FKA Watson Laboratories Inc., Lupin Pharmaceuticals, Inc., and Lupin LTD infringed patent no. 8,435,944, Method and Composition for Transdermal Drug Delivery (the ‘944 patent) and 8,807,861,… [read post]
1 Dec 2017, 11:35 am
Big pharma players such as Eli Lilly, Novo Nordisk and Allergan are committed to voluntary price restraints, while companies such as Novartis and Roche are in favor of value-based pricing. [read post]
1 Dec 2017, 6:20 am
The Swiss Federal Patent court had originally denied the infringement of Eli Lilly's patent but the Supreme Court granted Eli Lilly, a remarkable event in itself. [read post]
30 Nov 2017, 11:11 am
X ZR 29/15, GRUR 2016/921 (Eli Lilly v Actavis), paras. 83-85). [read post]
28 Nov 2017, 1:05 pm
Therein, we found this excerpt concerning lower limb amputations: These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) at the American Heart Association® (AHA) Scientific Sessions 2017 in Anaheim, Calif. and simultaneously published online [as a Research Letter: "Cardiovascular Outcomes and Safety of Empagliflozin in Patients With… [read post]
24 Nov 2017, 7:07 am
Brian CorderyFew would dispute that the Actavis v Eli Lilly decision from the Supreme Court in July 2017 represented – for better or for worse – a major change to the scope of protection of patents in the UK. [read post]
23 Nov 2017, 12:13 am
He gave the example of Eli Lilly which tried to develop a cure against Alzheimer’s disease, invested over a US$ billion and spent ten years in R&D to no avail. [read post]
21 Nov 2017, 1:25 pm
Eli Lilly and Teva have been involved in numerous patent infringement lawsuits against each other in the past. [read post]
18 Nov 2017, 9:00 pm
He is a past director of global corporate affairs for Elanco, a subsidiary of Eli Lilly and Company. [read post]
16 Nov 2017, 9:30 pm
Bush Administration and has worked for the drug company Eli Lilly. [read post]
13 Nov 2017, 1:59 pm
If approved, Alex Azar will succeed Tom Price, who resigned from the post amid controversy. [read post]
9 Nov 2017, 9:04 am
Eric Sutton is a senior patent counsel at Oracle and an adjunct professor at Chicago-Kent College of Law. [read post]
9 Nov 2017, 1:55 am
Entrance to the Swiss Federal Supreme CourtSince we are on the topic of K = Na, here a short update on the Swiss arm of the litigation.The Swiss Federal Patent Court considered the prosecution history and denied infringement of Eli Lilly’s patent by equivalent means because of the limitation introduced by the patentee during the examination. [read post]
8 Nov 2017, 10:48 pm
THE VOTE - has the decision in Actavis v Eli Lilly improved the law? [read post]
8 Nov 2017, 5:29 am
Part 2 covers claims with numerical limits, relevance of the file history, harmonisation, and a vote as to whether the decision in Actavis v Eli Lilly has improved the law. [read post]
7 Nov 2017, 11:36 am
The most recent medical journal article we have seen concerning this drug safety issue singles out the SGLT2 inhibitors which contain the active empagliflozin, which are listed below: Jardiance (empagliflozin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2014 Glyxambi (empagliflozin and linagliptin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2015 Synjardy (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and… [read post]
7 Nov 2017, 3:26 am
It is not known whether Eli Lilly will seek to obtain permission to appeal from the Supreme Court. [read post]
31 Oct 2017, 12:05 am
Patent practitioners have been speculating in recent weeks about what the Actavis v Eli Lilly Supreme Court judgment means in practice and how that decision might be applied. [read post]
28 Oct 2017, 8:57 am
Citing CJEU case law (C-322/10 ”Medeva” and C-493/12 ”Eli Lilly”) as well as the DKPTO Guide Lines on SPCs – which state that a combination product consisting in the two active ingredients A and B are considered as protected, when A and B are stated in a patent claim – the Court concluded that ”Emtricitabin does not appear in the wording of claim 27, just as emtricitabin is not described by way of chemical name or structural formula or… [read post]
26 Oct 2017, 7:31 am
Brian Corderyby Rachel Mumby Patent lawyers in the UK have spent the last three months pondering, debating and at times indulging in an element of despair (to put it mildly) about what might be the impact of the judgment of the Supreme Court in Actavis v Eli Lilly [2017] UKSC 48 on issues of validity (see here). [read post]
